Approval · Notice of Compliance 29619 · 2022
ATRIANCE: Notice of Compliance 29619
Issued November 30, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29619
- Date
- November 30, 2022
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATRIANCE | 02299925 | Marketed |
Medicinal ingredients
- NELARABINE 5 MG per ML